Azilsartan Medoxomil: A New Angiotensin Receptor Blocker
Clinical Therapeutics, 2011 Azilsartan medoxomil is an angiotensin receptor blocker, approved on February 25, 2011 by the US Food and Drug Administration (FDA) for hypertension management.The purpose of this study was to review the pharmacology, pharmacokinetics, efficacy, safety profile, and role of azilsartan for hypertension management.Peer-reviewed clinical trials, review ...
exaly +6 more sources
Open Chemistry, 2021 Five various chemometric methods were established for the simultaneous determination of azilsartan medoxomil (AZM) and chlorthalidone in the presence of azilsartan which is the core impurity of AZM.
Ahmed H Bakheit +2 more
exaly +2 more sources
MODERN OPPORTUNITIES FOR ANTIHYPERTENSION THERAPY: THE PLACE OF AZILSARTAN MEDOXOMIL
Российский кардиологический журнал, 2017 Modern approaches to antihypertension therapy suppose the usage of combination drugs, making significant positive influence on the values of systemic blood pressure (BP) in daily and nocturnal periods, optimization of 24-hour BP profile, achieved target ...
V. V. Skibitsky, A. V. Fendrikova
doaj +3 more sources
Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. [PDF]
J Clin Hypertens (Greenwich), 2017 This 52‐week, randomized, open‐label study evaluated long‐term safety/tolerability of fixed‐dose combination azilsartan medoxomil/chlorthalidone (AZL‐M/CLD) vs fixed‐dose combination olmesartan medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with essential hypertension (stage 2; clinic systolic blood pressure 160–190 mm Hg).
Neutel JM +4 more
europepmc +4 more sources
Spectrophotometric and spectrofluorimetric studies on azilsartan medoxomil and chlorthalidone to be utilized in their determination in pharmaceuticals. [PDF]
Anal Chem Insights, 2014 The recently approved angiotensin II receptor blocker, azilsartan medoxomil (AZL), was determined spectrophotometrically and spectrofluorimetrically in its combination with chlorthalidone (CLT) in their combined dosage form. The UV-spectrophotometric technique depends on simultaneous measurement of the first derivative spectra for AZL and CLT at 286 ...
Ebeid WM +4 more
europepmc +4 more sources
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. [PDF]
Blood Press Monit, 2014 The aim of the study was to measure the effects on blood pressure (BP) of the angiotensin receptor blocker azilsartan medoxomil, in 40 and 80 mg doses, combined with 5 mg of the calcium channel blocker amlodipine and to compare these effects with placebo plus amlodipine 5 mg.This was a randomized, controlled, double-blind study of 6 weeks' duration in ...
Weber MA +6 more
europepmc +4 more sources
Looking for an optimal antihypertensive combination. Focus on azilsartan medoxomil/chlorthalidone
Российский кардиологический журналThe article analyzes data from clinical studies on the efficacy and safety of azilsartan medoxomil/chlorthalidone combination and its components. According to the analyzed sources, both individual components and their combination have proven their ...
M. D. Smirnova +2 more
doaj +2 more sources
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. [PDF]
J Clin Hypertens (Greenwich), 2011 The current study assesses the antihypertensive efficacy and safety of the investigational angiotensin receptor blocker (ARB), azilsartan medoxomil (AZL‐M), compared with placebo and the ARB olmesartan medoxomil (OLM‐M). This randomized, double‐blind, placebo‐controlled, multicenter study assessed change from baseline in mean 24‐hour ambulatory ...
Bakris GL +7 more
europepmc +4 more sources
Authors’ Reply: Safety of combination therapy of azilsartan medoxomil and amlodipine: a population-based cohort study [PDF]
Epidemiology and HealthHyesung Lee +9 more
doaj +2 more sources
Letter to the Editor: Safety of combination therapy of azilsartan medoxomil and amlodipine: a population-based cohort study [PDF]
Epidemiology and HealthZhanyi Zhou
doaj +2 more sources